Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 23, 2026 07:30 ET | Source: Alveus Therapeutics Inc

Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity

PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation...
January 09, 2026 03:13 ET | Source: Alveus Therapeutics Inc

Alveus Therapeutics annoncerer serie A-financiering på 160 mio. USD til næste generations behandlinger mod fedme og stofskiftesygdomme

Financieringen går til fase 2-udvikling af ALV-100, IND-indsendelse af ALV-200 samt fremme af flere udviklingsprogrammer ALV-100, en bifunktionel GIPR-antagonist/GLP-1R-agonist, udviklet til varig...
January 08, 2026 07:30 ET | Source: Alveus Therapeutics Inc

Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases

Financing supports Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist,...